Sponsor hub

Assistance Publique - Hôpitaux de Paris clinical trial failures

Review 74 stopped clinical trials from Assistance Publique - Hôpitaux de Paris, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 8 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials74
Likely biological signals8
Shown below74

Dominant stop reasons

OTHER/UNKNOWN
40
OPERATIONAL
26
SAFETY
5
EFFICACY/FUTILITY
3

Notable sponsors

Assistance Publique - Hôpitaux de Paris
74

Related phases

Phase III
27
Phase II
26
Phase IV
11
Unknown
7
Phase I
3

Crawlable stopped-trial records

Open Explore

Showing up to 74 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT04275778: HYDROxychloroquine in Syndrome Primary AntiPhospholipid

Phase II Antiphospholipid Syndrome in Pregnancy trial by Assistance Publique - Hôpitaux de Paris. Stop reason: OTHER/UNKNOWN.

The study was terminated following revisions to the diagnostic criteria defining the target pathology, which significantly impacted the study design

NCT05238896: BARIcitinib Cognitive Emotional and Neural signaTuRE

Phase IV Rheumatoid Arthritis trial by Assistance Publique - Hôpitaux de Paris. Stop reason: OTHER/UNKNOWN.

Difficulties of inclusion in the study following expiry of the experimental treatment. The time required to supply the study treatment is too long to obtain conclusive results at the end of the study.

NCT03090880: Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)

Phase III Venous Thromboembolism trial by Assistance Publique - Hôpitaux de Paris. Stop reason: OTHER/UNKNOWN.

The rate of inclusion is too low to hope to reach the target of 800 patients. 59 patients were included, and their data will not meet the research objectives. The sponsor has decided to prematurely stop inclusions on January 13, 2022.